Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Barbara Sarb

Pain Medicine Florence, SC Doctor of Osteopathy

NPI 1285691485 CMS profile 194687

1204 E Cheves St, Florence, SC 29506

Open in the dashboard

General payments

$11,026

263 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Barbara Sarb of Florence, SC is reported in the CMS Open Payments database as having received $11,026 across 263 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,998 34
2024 General $2,099 50
2023 General $1,882 43
2022 General $974 32
2021 General $797 27
2020 General $1,149 34
2019 General $1,128 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barbara Sarb
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Barbara Sarb were reported at $2,998. Among 95 Pain Medicine profiles paid that year, the median was $405 and the middle half received between $116 and $1,740.

Show as a table
Year Barbara Sarb Pain Medicine median Middle half National median
2019 $1,128 $298 $103–$1,153 $163
2020 $1,149 $188 $57–$916 $114
2021 $797 $365 $109–$1,150 $132
2022 $974 $498 $104–$1,575 $149
2023 $1,882 $334 $108–$1,267 $160
2024 $2,099 $544 $144–$1,302 $164
2025 $2,998 $405 $116–$1,740 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,976 110 payments
  2. Nevro Corp. $2,361 71 payments
  3. Stryker Corporation $1,841 12 payments
  4. Abbott Laboratories $1,390 14 payments
  5. Nalu Medical, Inc. $1,027 9 payments
  6. Globus Medical, Inc. $633 14 payments
  7. Curonix LLC $359 12 payments
  8. Vertos Medical, Inc. $85 4 payments
  9. SI-BONE, Inc. $76 2 payments
  10. Electronic Waveform Lab, Inc. $67 1 payment
  11. Other $211 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,546 240 payments
  2. Travel and Lodging $4,479 23 payments
Products named General payments · program years 2019–2025
  1. Senza Spinal Cord Stimulator $1,180 34 payments
  2. PROCLAIM $1,170 8 payments
  3. Nalu Neurostimulation System $1,027 9 payments
  4. IVS - VERTEBRAL AUGMENTATION PRODUCTS $898 6 payments
  5. MILD DEVICE KIT $859 3 payments
  6. Omnia $751 18 payments
  7. Senza Spinal Cord Stimulator $633 14 payments
  8. GENERAL PAIN MANAGEMENT $461 10 payments
  9. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $359 12 payments
  10. WaveWriter Alpha Prime 16 $354 22 payments
  11. Other $2,305 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

20

Median for Neurology: 833

Drug cost

$166

Median for Neurology: $202,670

Branded share of claims

0%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 20 $166

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$111,862

Of which drugs: $521

Medicare patients

267

Average age 76

Services billed

2,927

135 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 28%
Ischemic heart disease 27%
Chronic kidney disease 19%
Cancer 17%
Depression 16%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 51 457 $347
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 41 931 $82
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 71 238 $69

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record